A Note from Biosimilars Council Executive Director Christine Simmon
September was an exciting month, as we announced the topline findings of our forthcoming 2021 Generic Drug and Biosimilars Savings in the U.S. Report, which once again shows the tremendous savings generated by biosimilars. The report, coming out in October, finds that biosimilar savings more than tripled to nearly $8 billion. Additionally, oncology biosimilars have cut the growth rate for oncology spending roughly in half since 2019. Read our full statement here.
I hope you can join the GRx+Biosims 2021 conference November 8-10, 2021 to discuss the positive news from the savings report and the future of biosimilar medicines in the United States. This year’s event will be held virtually. More information on the biosimilar sessions is here, and please be sure to register. To learn about sponsorship opportunities, please contact us through this form.